We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+16.83%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.49B
AUM Growth
+$21.6M
Cap. Flow
+$155M
Cap. Flow %
6.21%
Top 10 Hldgs %
58.42%
Holding
119
New
16
Increased
22
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$27.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$23.7M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.2M
4
MDCO
Medicines Co
MDCO
+$16M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$14.8M

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$37M
2
AVTR icon
Avantor
AVTR
+$16.9M
3
Z icon
Zillow
Z
+$13.9M
4
BPMC
Blueprint Medicines
BPMC
+$13M
5
HTHT icon
Huazhu Hotels Group
HTHT
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 49.17%
2 Consumer Discretionary 26.12%
3 Technology 2.9%
4 Communication Services 0.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WW
1
DELISTED
WW International
WW
$560M 22.47%
14,818,300
– –
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.03B
$181M 7.27%
60,240,864
– –
BMY icon
3
CALL
Bristol-Myers Squibb
BMY
$129B
$177M 7.12%
3,500,000
+1,250,000
+56% +$58.7M
AVTR icon
4
Avantor
AVTR
$9.48B
$88.2M 3.54%
6,000,000
-1,000,000
-14% -$16.9M
BAC icon
5
CALL
Bank of America
BAC
$435B
$87.5M 3.51%
+3,000,000
New +$86.3M
ONC
6
BeOne Medicines Ltd
ONC
$34B
$79.6M 3.19%
650,000
– –
BABA icon
7
Alibaba
BABA
$275B
$75.3M 3.02%
450,000
– –
MRNA icon
8
Moderna
MRNA
$22B
$73.3M 2.94%
4,606,298
– –
MDCO
9
DELISTED
Medicines Co
MDCO
$70M 2.81%
1,400,000
+400,000
+40% +$16M
MS icon
10
CALL
Morgan Stanley
MS
$323B
$64M 2.57%
+1,500,000
New +$64.1M
XLRN
11
DELISTED
Acceleron Pharma
XLRN
$59.3M 2.38%
1,500,000
– –
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$38.6B
$56.3M 2.26%
700,000
+300,000
+75% +$23.7M
BPMC
13
DELISTED
Blueprint Medicines
BPMC
$44.1M 1.77%
600,000
-150,000
-20% -$13M
NVDA icon
14
NVIDIA
NVDA
$4.67T
$34.8M 1.4%
8,000,000
-8,800,000
-52% -$37M
MORF
15
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$32.9M 1.32%
1,819,186
+1,319,186
+264% +$27.6M
FATE icon
16
Fate Therapeutics
FATE
$269M
$31.1M 1.25%
2,000,000
+500,000
+33% +$9.58M
GOSS icon
17
Gossamer Bio
GOSS
$97.2M
$27M 1.08%
1,608,968
– –
ARGX icon
18
argenx
ARGX
$55.4B
$22.8M 0.91%
200,000
-20,000
-9% -$2.7M
RUBY
19
DELISTED
Rubius Therapeutics, Inc
RUBY
$22.2M 0.89%
2,833,791
– –
ATRA icon
20
Atara Biotherapeutics
ATRA
$70.5M
$21.2M 0.85%
60,000
+14,000
+30% +$5.22M
SAGE
21
DELISTED
Sage Therapeutics
SAGE
$21M 0.84%
150,000
– –
SRRK icon
22
Scholar Rock
SRRK
$5.96B
$21M 0.84%
2,346,040
– –
FOLD
23
DELISTED
Amicus Therapeutics
FOLD
$20.1M 0.8%
2,500,000
– –
Z icon
24
Zillow
Z
$7.81B
$19.4M 0.78%
650,000
-350,000
-35% -$13.9M
XBI icon
25
CALL
State Street SPDR S&P Biotech ETF
XBI
$10B
$19.1M 0.76%
+250,000
New +$20.8M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2019 Portfolio in Review

As of Q3 2019, Artal Group held 119 positions worth $2.49B, up 0.87% from $2.47B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Artal Group deployed $155M of net new capital in Q3 2019, opening 16 new positions and adding to 22 existing holdings. Its largest new stake was Global Blood Therapeutics, Inc.: 350,000 shares worth $17M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 63% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was NVIDIA, an estimated $37M trimmed.

  • Artal Group's largest Q3 2019 buy was Global Blood Therapeutics, Inc.: 350,000 shares worth $17M.
  • Artal Group added most to Morphic Holding, Inc. Common Stock in Q3 2019, an estimated $27.6M increase.
  • Artal Group's biggest Q3 2019 reduction was NVIDIA, cutting an estimated $37M.
  • Artal Group fully exited Huazhu Hotels Group in Q3 2019, selling an estimated $12.7M.
  • Artal Group's ten largest holdings make up 58% of its $2.49B portfolio in Q3 2019.
  • Artal Group opened 16 new positions and closed 17 in Q3 2019.
  • Artal Group's portfolio value rose 0.87% quarter-over-quarter to $2.49B.

Based on Artal Group's 13F filing for Q3 2019, filed 14 Nov 2019.